Subject:
- Active Substance: Ciltacaptagene autoleucel
- Name: Carvykti®
- Therapeutic area: Multiple myeloma
- Pharmaceutical company: Janssen-Cilag GmbH
Time table:
- Start: 15.02.2023
- Final decision by G-BA: 17.08.2023
- The decision remains valid until: 01.07.2026
Final decision:
- Hint for a non-quantifiable additional benefit